In The News,
Lindsay Bealor Greenleaf talks to The Street about the Senate HELP Committee hearing on the Trump Administration’s Drug Pricing Blueprint
[el-text]
Written by Bill Meagher
***excerpt***
“It was great to hear Secretary Azar emphasize the need to reform the role played by PBMs,” said Lindsay Bealor Greenleaf, a director at advisory firm ADVI Health, via email. “But his plan for moving Medicare Part B drug coverage into Part D is concerning.”
***end excerpt***
***
[/el-text]